Supernus Pharmaceuticals | SUPN - Operating Expenses


Supernus Pharmaceuticals reported $252.29M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Abbott USD 9.21B 17M Dec/2025
ANI Pharmaceuticals USD 505.82M 309.62M Sep/2025
Aurora Cannabis CAD 146.03M 27.79M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Canopy Growth CAD 80.99M 8.64M Sep/2025
Cara Therapeutics USD 4.96M 2.38M Mar/2025
Corcept Therapeutics USD 197.42M 29.66M Sep/2025
Eisai JPY 199.9B 16.22B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Novo Nordisk DKK 46.76B 3.99B Dec/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025
United Therapeutics USD 6.59B 6.07B Sep/2025
Xeris Pharmaceuticals USD 67.65M 590K Sep/2025